Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28340912 | 0.92 | ALDH1A1 (0.57) | ALDH1A1HTTNPC1POLBRAB9A | |
| SCHEMBL3292480 | 0.90 | ALDH1A1 (0.50) | ALDH1A1HTTNPC1POLBRAB9A | |
| SCHEMBL8021350 | 0.85 | ALDH1A1 (0.78) | ALDH1A1POLBMMP9MMP1MMP2 | |
| SCHEMBL3758807 | 0.84 | ALDH1A1 (0.60) | ALDH1A1HTTNPC1POLBRAB9A | |
| SCHEMBL292834 | 0.84 | ALDH1A1 (0.60) | ALDH1A1HTTNPC1POLBRAB9A | |
| SCHEMBL13892960 | 0.84 | ALDH1A1 (0.64) | ALDH1A1NPC1POLBSMN1; SMN2MAPT | |
| SCHEMBL6403295 | 0.82 | ALDH1A1 (0.58) | ALDH1A1HTTNPC1POLBRAB9A | |
| SCHEMBL292835 | 0.82 | NPC1 (0.59) | ALDH1A1HTTNPC1POLBRAB9A | |
| SCHEMBL112518 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HTTNPC1POLBRAB9A | |
| SCHEMBL1871228 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HTTNPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627832-A | Preparation method for synthesizing tenofovir alafenamide by oxidation method | 江西农业大学 | 2019-12-31 | — | — | CN | claimed |
| US-20250355350-A1 | NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED COATING, INTERLAYER INSULATING FILM, SURFACE PROTECTING FILM, AND ELECTRONIC COMPONENT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4650874-A1 | NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED COATING, INTERLAYER INSULATING FILM, SURFACE PROTECTING FILM, AND ELECTRONIC COMPONENT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4636485-A1 | NEGATIVE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC COMPONENT | Shin-Etsu Chemical Co., Ltd. (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12018122-B2 | Method for producing silane-modified polymers | MERZ+BENTELI AG (CH) | 2024-06-25 | — | — | US | disclosed |
| CN-118047785-A | Method for preparing Wu Pati Ni and intermediate thereof | 和鼎（南京）医药技术有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20230192594-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-06-22 | — | — | US | disclosed |
| EP-3877438-B1 | METHOD FOR THE PREPARATION OF SILANE-MODIFIED POLYMERS | MERZ BENTELI AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-113166358-B | Process for preparing silane-modified polymers | 默兹奔特利股份公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11613514-B2 | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-03-28 | — | — | US | disclosed |
| EP-0005507-A1 | Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby | CIBA-GEIGY AG (CH) | 1979-11-28 | — | — | EP | disclosed |
| EP-0001265-A1 | O-, N- and carboxyl derivatives of thienamycin sulfoxide and sulfone, their preparation and pharmaceuticals containing said compounds | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| US-4060687-A | Cephalosporins having a 3-α substituted alkyl grouping | MERCK & CO., INC. (US) | 1977-11-29 | — | — | US | disclosed |
| US-4060630-A | Ethylenediamine derivatives useful in treating sickle cell anemia | RICHARDSON-MERRELL INC. (US) | 1977-11-29 | — | — | US | disclosed |
| US-4010178-A | Carbonic acid esters, and the preparation thereof and their use | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-03-01 | — | — | US | disclosed |
| US-3962224-A | CHEMICAL INTERMEDIATES FOR ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3947413-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
| US-3936452-A | Process of producing pyrimidyl thiocarbonates | NITTO BOSEKI CO., LTD. (JA) | 1976-02-03 | — | — | US | disclosed |
| US-3932375-A | PROTECTING GROUPS | NITTO BOSEKI CO. LTD. (JA) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192594-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | GRM6, HYPK, SYMPK | ALDH1A1 2671/4885HTT 106/4885NPC1 4410/4885 |
| US-11613514-B2 | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine | PDXK, GCK, KHK | ALDH1A1 2958/4885HTT 60/4885NPC1 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.